Latest

Coherus Publication in Molecular Cancer Therapeutics Highlights Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug

LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma

Coherus sells its last biosimilar Udenyca to Intas for up to $558M as company homes in on novel cancer meds

CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Cellworks Personalized Therapy Biosimulation Study Produces Superior OS and DFS Predictions for Gastroesophageal Cancer Patients

Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Car

OncoResponse Awarded $13 Million in Funding from CPRIT to Advance Cancer Immunotherapy

Scientific Inquirer: Industry Matters: From Elite Responders to M2 macrophages – OncoResponse’s approach to cancer immunotherapy